|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shah MA: Update on metastatic gastric and
esophageal cancers. J Clin Oncol. 33:1760–1769. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Van Cutsem E, Sagaert X, Topal B,
Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zou YR, Kottmann AH, Kuroda M, Taniuchi I
and Littman DR: Function of the chemokine receptor CXCR4 in
haematopoiesis and in cerebellar development. Nature. 393:595–599.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cojoc M, Peitzsch C, Trautmann F,
Polishchuk L, Telegeev GD and Dubrovska A: Emerging targets in
cancer management: Role of the CXCL12/CXCR4 axis. Onco Targets
Ther. 6:1347–1361. 2013.PubMed/NCBI
|
|
6
|
Ying J, Xu Q, Zhang G, Liu B and Zhu L:
The expression of CXCL12 and CXCR4 in gastric cancer and their
correlation to lymph node metastasis. Med Oncol. 29:1716–1722.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang X, Zhang H, He H, Shen Z, Tang Z, Xu
J and Sun Y: Prognostic value of stromal cell-derived factor 1
expression in patients with gastric cancer after surgical
resection. Cancer Sci. 105:1447–1456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ohtsu H, Dempsey PJ and Eguchi S: ADAMs as
mediators of EGF receptor transactivation by G protein-coupled
receptors. Am J Physiol Cell Physiol. 291:C1–10. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hart S, Fischer OM, Prenzel N,
Zwick-Wallasch E, Schneider M, Hennighausen L and Ullrich A:
GPCR-induced migration of breast carcinoma cells depends on both
EGFR signal transactivation and EGFR-independent pathways. Biol
Chem. 386:845–855. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kasina S, Scherle PA, Hall CL and Macoska
JA: ADAM-mediated amphiregulin shedding and EGFR transactivation.
Cell Prolif. 42:799–812. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yasumoto K, Yamada T, Kawashima A, Wang W,
Li Q, Donev IS, Tacheuchi S, Mouri H, Yamashita K, Ohtsubo K and
Yano S: The EGFR ligands amphiregulin and heparin-binding egf-like
growth factor promote peritoneal carcinomatosis in CXCR4-expressing
gastric cancer. Clin Cancer Res. 17:3619–3630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Natarajan K and Berk BC: Crosstalk
coregulation mechanisms of G protein-coupled receptors and receptor
tyrosine kinases. Methods Mol Biol. 332:51–77. 2006.PubMed/NCBI
|
|
13
|
Hopkins MM, Liu Z and Meier KE: Positive
and negative cross-talk between lysophosphatidic acid receptor 1,
free fatty acid receptor 4, and epidermal growth factor receptor in
human prostate cancer cells. J Pharmacol Exp Ther. 359:124–133.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fischer OM, Giordano S, Comoglio PM and
Ullrich A: Reactive oxygen species mediate Met receptor
transactivation by G protein-coupled receptors and the epidermal
growth factor receptor in human carcinoma cells. J Biol Chem.
279:28970–28978. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chinni SR, Yamamoto H, Dong Z, Sabbota A,
Bonfil RD and Cher ML: CXCL12/CXCR4 transactivates HER2 in lipid
rafts of prostate cancer cells and promotes growth of metastatic
deposits in bone. Mol Cancer Res. 3:446–457. 2008. View Article : Google Scholar
|
|
16
|
Martin GS: The hunting of the Src. Nat Rev
Mol Cell Biol. 2:467–475. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bendinelli P, Maroni P, Matteucci E and
Desiderio MA: Comparative role of acetylation along c-SRC/ETS1
signaling pathway in bone metastatic and invasive mammary cell
phenotypes. Biochim Biophys Acta. 1813:1767–1776. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Luttrell LM, Ferguson SS, Daaka Y, Miller
WE, Maudsley S, Rocca GJ Della, Lin F, Kawakatsu H, Owada K,
Luttrell DK, et al: Beta-arrestin-dependent formation of beta2
adrenergic receptor-Src protein kinase complexes. Science.
283:655–661. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang S, Huang WC, Li P, Guo H, Poh SB,
Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, et al: Combating
trastuzumab resistance by targeting SRC, a common node downstream
of multiple resistance pathways. Nat Med. 17:461–469. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stabile LP, He G, Lui VW, Thomas S, Henry
C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM and Grandis JR:
c-Src activation mediates erlotinib resistance in head and neck
cancer by stimulating c-Met. Clin Cancer Res. 19:380–392. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peiró G, Ortiz-Martínez F, Gallardo A,
Pérez-Balaguer A, Sánchez-Payá J, Ponce JJ, Tibau A, López-Vilaro
L, Escuin D, Adrover E, et al: SRC, a potential target for
overcoming trastuzumab resistance in HER2-positive breast
carcinoma. Br J Cancer. 111:689–695. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boerner JL: Role of SRC family kinases in
acquired resistance to EGFR therapies in cancer. Cancer Biol Ther.
8:704–706. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu L, Qu X, Li H, Li C, Liu J, Zheng H and
Liu Y: Src/caveolin-1-regulated EGFR activation antagonizes
TRAIL-induced apoptosis in gastric cancer cells. Oncol Rep.
32:318–324. 2014.PubMed/NCBI
|
|
24
|
Zhao L, Liu S, Che X, Hou K, Ma Y, Li C,
Wen T, Fan Y, Hu X, Liu Y and Qu X: Bufalin inhibits TGF-β-induced
epithelial-to-mesenchymal transition and migration in human lung
cancer A549 cells by downregulating TGF-β receptors. Int J Mol Med.
36:645–652. 2015.PubMed/NCBI
|
|
25
|
DiPersio JF, Uy GL, Yasothan U and
Kirkpatrick P: Plerixafor. Nat Rev Drug Discov. 8:105–106. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nagasawa T, Hirota S, Tachibana K,
Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H and
Kishimoto T: Defects of B-cell lymphopoiesis and bone-marrow
myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature.
382:635–638. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ratajczak MZ, Zuba-Surma E, Kucia M, Reca
R, Wojakowski W and Ratajczak J: The pleiotropic effects of the
SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis.
Leukemia. 20:1915–1924. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guo G, Gong K, Wohlfeld B, Hatanpaa KJ,
Zhao D and Habib AA: Ligand-independent EGFR signaling. Cancer Res.
75:3436–3441. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bhola NE and Grandis JR: Crosstalk between
G-protein-coupled receptors and Epidermal growth factor receptor in
cancer. Front Biosci. 13:1857–1865. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Porcile C, Bajetto A, Barbieri F, Barbero
S, Bonavia R, Biglieri M, Pirani P, Florio T and Schettini G:
Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates
ovarian cancer cell growth through the EGF receptor
transactivation. Exp Cell Res. 308:241–253. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bromann PA, Korkaya H and Courtneidge SA:
The interplay between Src family kinases and receptor tyrosine
kinases. Oncogene. 23:7957–7968. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Parsons JT and Parsons SJ: Src family
protein tyrosine kinases: Cooperating with growth factor and
adhesion signaling pathways. Curr Opin Cell Biol. 9:187–192. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dittmann K, Mayer C, Kehlbach R, Rothmund
MC and Rodemann H Peter: Radiation-induced lipid peroxidation
activates src kinase and triggers nuclear EGFR transport. Radiother
Oncol. 92:379–382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Song N, Liu S, Zhang J, Liu J, Xu L, Liu Y
and Qu X: Cetuximab-induced MET activation acts as a novel
resistance mechanism in colon cancer cells. Int J Mol Sci.
15:5838–5851. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
de Nigris F, Schiano C, Infante T and
Napoli C: CXCR4 inhibitors: Tumor vasculature and therapeutic
challenges. Recent Pat Anticancer Drug Discov. 7:251–264. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mayer EL and Krop IE: Advances in
targeting SRC in the treatment of breast cancer and other solid
malignancies. Clin Cancer Res. 16:3526–3532. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Montero JC, Seoane S, Ocaña A and
Pandiella A: Inhibition of SRC family kinases and receptor tyrosine
kinases by dasatinib: Possible combinations in solid tumors. Clin
Cancer Res. 17:5546–5552. 2011. View Article : Google Scholar : PubMed/NCBI
|
